Source comparison
10mg vs 15mg vs 25mg: Research Application Breakdown
At 10mg daily, MK-677 produces approximately 60% elevation in mean 24-hour GH levels compared to baseline, with IGF-1 increases in the range of 40–60 ng/mL depending on baseline levels. This dose is ideal for studies prioritizing long-term administration (16+
This comparison does not assign a generated winner or score.
- At 10mg daily, MK-677 produces approximately 60% elevation in mean 24-hour GH levels compared to baseline, with IGF-1 increases in the range of 40–60 ng/mL depending on baseline levels. This dose is ideal for studies prioritizing long-term administration (16+ weeks) where metabolic side effects must be minimized. Research applications include sleep architecture studies. MK-677 at 10mg extends Stage 4 sleep duration by 50% in older populations. And geriatric muscle preservation models where appetite stimulation is a feature, not a bug.
- Side effects at 10mg are minimal in most research models: transient water retention (2–3kg in the first two weeks), mild appetite increase, and occasional morning lethargy. Fasting glucose elevation is rare at this dose unless the research subject has pre-existing insulin resistance. Our experience with this tier: it's the only dose sustainable beyond 20 weeks without significant metabolic drift.
- 15mg daily represents the efficacy sweet spot for most anabolic research contexts. GH elevation reaches 75–85% above baseline, IGF-1 climbs 60–90 ng/mL, and nitrogen retention improves measurably within three weeks. This is the dose tier used in most published lean mass preservation studies. It delivers meaningful anabolic signaling without the glucose dysregulation that 25mg introduces.
- Appetite increase is pronounced at 15mg. Expect 20–30% caloric intake elevation if food is ad libitum. This makes 15mg unsuitable for fat loss research models but advantageous for muscle gain or recovery protocols. Water retention peaks at week two (3–5kg), then stabilizes. Fasting glucose may rise 5–10 mg/dL; this is typically reversible post-cycle but requires monitoring in metabolic research contexts.
- 25mg daily maximizes GH output. Studies show 90–100% GH elevation and IGF-1 increases exceeding 100 ng/mL in some subjects. This dose is reserved for short-duration research protocols (6–8 weeks maximum) where peak anabolic signaling justifies the metabolic trade-offs. Applications include acute injury recovery models, severe cachexia studies, or investigational uses where GH elevation itself is the primary endpoint.
- Side effects scale sharply: appetite becomes dysregulated (40–50% caloric surplus common), fasting glucose rises 10–20 mg/dL on average, and insulin sensitivity declines measurably by week four. A subset of research models develop symptoms consistent with pre-diabetic glucose handling. Fasting glucose above 100 mg/dL, elevated HbA1c. Which is why 25mg protocols require biweekly metabolic panels. Water retention can reach 6–8kg in the first month. Lethargy and CNS fatigue are reported in 30–40% of cases.